Pharmaceutical 2/2

top of page

WSE_logo_artwork-rgb_outline_dark green.png

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Novo Nordisk’s $23 Billion Growth Plan Fails to Reassure Investors

Pharma Investments

Sep 212 min read

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

MapLight’s Schizophrenia Drug Worked, but Can It Compete?

Sep 162 min read

GSK’s Cancer Comeback Just Passed Another Important Test

GSK’s Cancer Comeback Just Passed Another Important Test

GSK’s Cancer Comeback Just Passed Another Important Test

Sep 153 min read

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Eli Lilly's Next Obesity Drug Could Raise the Bar Again

Sep 142 min read

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Tempus Isn't Just Buying a Cancer Testing Company, It's Buying an AI Advantage

Sep 142 min read

The AI Drug Revolution Is Finally Facing Its Biggest Test

The AI Drug Revolution Is Finally Facing Its Biggest Test

The AI Drug Revolution Is Finally Facing Its Biggest Test

Sep 142 min read

Eli Lilly's Latest Acquisition Isn't Just About One Drug It's About the Future of Mental Health

Eli Lilly's Latest Acquisition Isn't Just About One Drug It's About the Future of Mental Health

Eli Lilly's Latest Acquisition Isn't Just About One Drug It's About the Future of Mental Health

Sep 142 min read

Merck Isn't Reinventing Cholesterol Drugs It's Reinventing How Patients Use Them

Merck Isn't Reinventing Cholesterol Drugs It's Reinventing How Patients Use Them

Merck Isn't Reinventing Cholesterol Drugs It's Reinventing How Patients Use Them

Sep 142 min read

Cancer treatment could identify patients most likely to respond to cancer drugs

Cancer treatment could identify patients most likely to respond to cancer drugs

Cancer treatment could identify patients most likely to respond to cancer drugs

Aug 102 min read

Trump’s Drug Pricing Push Could Put Smaller Pharma Firms Under Pressure

Trump’s Drug Pricing Push Could Put Smaller Pharma Firms Under Pressure

Trump’s Drug Pricing Push Could Put Smaller Pharma Firms Under Pressure

Aug 101 min read

Renalytix Surges 24% as Long-Term Data Strengthens the Investment Story

Renalytix Surges 24% as Long-Term Data Strengthens the Investment Story

Renalytix Surges 24% as Long-Term Data Strengthens the Investment Story

Aug 102 min read

Generative AI’s First Real-World Health Test

Generative AI’s First Real-World Health Test

Generative AI’s First Real-World Health Test

Feb 233 min read

UK-US Zero Tariff Deal on Pharmaceuticals

UK-US Zero Tariff Deal on Pharmaceuticals

UK-US Zero Tariff Deal on Pharmaceuticals

Dec 2, 20252 min read

bottom of page